A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)

  • Arulananda, Surein (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

HREC Reference Number: 2022/ETH00731
SSA Reference Number: SSA/94800/MonH-2023-363086(v1)
Monash Health Local Reference: RES-23-0000-223X
AcronymSAFFRON
StatusActive
Effective start/end date29/05/23 → 28/05/28